Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Oct 04, 2019
- Lung function data from the STRIDE Registry show a trend toward delay of decline of pulmonary function compared with those in CINRG Duchenne Natural History1 -     SOUTH PLAINFIELD, N.J. , Oct. 4, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that data from STRIDE,*
Additional Formats
Oct 02, 2019
- Risdiplam-treated type 1 babies with SMA continue to achieve major motor milestones-   - Risdiplam-treated patients in SUNFISH demonstrate clinically meaningful increases in muscle function/performance compared to natural history -   -All clinical trials involving risdiplam continue to
Additional Formats
Sep 27, 2019
  SOUTH PLAINFIELD, N.J. , Sept. 27, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Cantor Global Healthcare Conference Friday, October 4 th at 10:40 a.m.
Additional Formats
Sep 20, 2019
SOUTH PLAINFIELD, N.J. , Sept. 20, 2019 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on September 18, 2019 it approved non-statutory stock options to purchase an aggregate of 211,500 shares of its common stock to 48 new employees.
Additional Formats
Sep 18, 2019
SOUTH PLAINFIELD, N.J. , Sept. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it has priced its private offering of $250.0 million aggregate principal amount of its convertible senior notes due 2026 (the "Notes"). The Notes will be sold only to qualified
Additional Formats
Sep 18, 2019
SOUTH PLAINFIELD, N.J. , Sept. 18, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today the pricing of a public offering of 2,475,248 shares of its common stock at a public offering price of $40.40 per share, before underwriting discounts and commissions.
Additional Formats
Sep 17, 2019
SOUTH PLAINFIELD, N.J. , Sept. 17, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing a public offering of $100.0 million of shares of its common stock. PTC intends to grant the underwriter an option for a period of 30 days to purchase up to an
Additional Formats
Sep 17, 2019
SOUTH PLAINFIELD, N.J. , Sept. 17, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing an offering of $250.0 million aggregate principal amount of its convertible senior notes due 2026 (the "Notes"), subject to market conditions and other factors.
Additional Formats
Sep 06, 2019
-Global program recognizes excellence and innovation in the Duchenne muscular dystrophy community- -28 projects awarded funding since its inception- SOUTH PLAINFIELD, N.J. , Sept. 6, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's
Additional Formats
Aug 06, 2019
-Translarna™ approved in Brazil & PTC entered first annual contract with Ministry of Health- -Emflaza® receives FDA approval for a label expansion to treat DMD patients 2-5 years of age- -PTC expands gene therapy infrastructure & portfolio- SOUTH PLAINFIELD, N.J. , Aug.
Additional Formats